Outcomes of wavefront-optimized surface ablation.

J. Randleman,Evan S. Loft,C. Banning,Michael J. Lynn,R. Stulting

DOI: https://doi.org/10.1016/J.OPHTHA.2006.10.048

2007-05-01

Abstract:

What problem does this paper attempt to address?

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Chiqing Ying,Chang He,Kaijin Xu,Yongtao Li,Ying Zhang,Wei Wu

DOI: https://doi.org/10.3724/zdxbyxb-2022-0445

2022-01-01

Journal of Zhejiang University (Medical Sciences)

Abstract:One fourth of the global population has been infected with Mycobacterium tuberculosis, and about 5%-10% of the infected individuals with latent tuberculosis infection (LTBI) will convert to active tuberculosis (ATB). Correct diagnosis and treatment of LTBI are important in ending the tuberculosis epidemic. Current methods for diagnosing LTBI, such as tuberculin skin test (TST) and interferon-γ release assay (IGRA), have limitations. Some novel biomarkers, such as transcriptome derived host genes in peripheral blood cells, will help to distinguish LTBI from ATB. More emphasis should be placed on surveillance in high-risk groups, including patients with HIV infection, those using biological agents, organ transplant recipients and those in close contact with ATB patients. For those with LTBI, treatment should be based on the risk of progression to ATB and the potential benefit. Prophylactic LTBI regimens include isoniazid monotherapy for 6 or 9 months, rifampicin monotherapy for 4 months, weekly rifapentine plus isoniazid for 3 months (3HP regimen) and daily rifampicin plus isoniazid for 3 months (3HR regimen). The success of the one month rifapentine plus isoniazid daily regimen (1HP regimen) suggests the feasibility of an ultra-short treatment strategy although its efficacy needs further assessment. Prophylactic treatment of LTBI in close contact with MDR-TB patients is another challenge, and the regimens include new anti-tuberculosis drugs such as bedaquiline, delamanid, fluoroquinolone and their combinations, which should be carefully evaluated. This article summarizes the current status of diagnosis and treatment of LTBI and its future development direction.
Optimal conditions for long-term photoreceptor cell rescue in RCS rats: the necessity for healthy RPE transplants.

Linxi Li,James E. Turner

DOI: https://doi.org/10.1016/0014-4835(91)90019-B

IF: 3.77

1991-06-01

Experimental Eye Research

Abstract:
Updates on the Risk Factors for Latent Tuberculosis Reactivation and Their Managements.

Jing-Wen Ai,Qiao-Ling Ruan,Qi-Hui Liu,Wen-Hong Zhang

DOI: https://doi.org/10.1038/emi.2016.10

2016-01-01

Emerging Microbes & Infections

Abstract:The preventive treatment of latent tuberculosis infection (LTBI) is of great importance for the elimination and control of tuberculosis (TB) worldwide, but existing screening methods for LTBI are still limited in predicting the onset of TB. Previous studies have found that some high-risk factors (including human immunodeficiency virus (HIV), organ transplantation, silicosis, tumor necrosis factor-alpha blockers, close contacts and kidney dialysis) contribute to a significantly increased TB reactivation rate. This article reviews each risk factor's association with TB and approaches to address those factors. Five regimens are currently recommended by the World Health Organization, and no regimen has shown superiority over others. In recent years, studies have gradually narrowed down to the preventive treatment of LTBI for high-risk target groups, such as silicosis patients, organ-transplantation recipients and HIV-infected patients. This review discusses regimens for each target group and compares the efficacy of different regimens. For HIV patients and transplant recipients, isoniazid monotherapy is effective in treating LTBI, but for others, little evidence is available at present.
Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

Timothy R. Sterling,Gibril Njie,Dominik Zenner,David L. Cohn,Randall Reves,Amina Ahmed,Dick Menzies,C. Robert Horsburgh,Charles M. Crane,Marcos Burgos,Philip LoBue,Carla A. Winston,Robert Belknap

DOI: https://doi.org/10.1111/ajt.15841

IF: 9.369

2020-03-28

American Journal of Transplantation

Abstract:Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were last published in 2000 (American Thoracic Society. Am J Respir Crit Care Med 161:S221‐S247, 2000) Since then, several new regimens have been evaluated in clinical trials. To update previous guidelines, the National Tuberculosis Controllers Association (NTCA) and CDC convened a committee to conduct a systematic literature review and make new recommendations for the most effective and least toxic regimens for treatment of LTBI among persons who live in the United States. The systematic literature review included clinical trials of regimens to treat LTBI. Quality of evidence (high, moderate, low, or very low) from clinical trial comparisons was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. In addition, a network meta‐analysis evaluated regimens that had not been compared directly in clinical trials. The effectiveness outcome was tuberculosis disease; the toxicity outcome was hepatotoxicity. Strong GRADE recommendations required at least moderate evidence of effectiveness and that the desirable consequences outweighed the undesirable consequences in the majority of patients. Conditional GRADE recommendations were made when determination of whether desirable consequences outweighed undesirable consequences was uncertain (eg with low‐quality evidence). These updated 2020 LTBI treatment guidelines include the NTCA‐ and CDC‐recommended treatment regimens that comprise three preferred rifamycin‐based regimens and two alternative monotherapy regimens with daily isoniazid. All recommended treatment regimens are intended for persons infected with Mycobacterium tuberculosis that is presumed to be susceptible to isoniazid or rifampin. These updated guidelines do not apply when evidence is available that the infecting M tuberculosis strain is resistant to both isoniazid and rifampin; recommendations for treating contacts exposed to multidrug‐resistant tuberculosis were published in 2019 (Nahid P, Mase SR Migliori GB, et al Treatment of drug‐resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019;200:e93‐e142). The three rifamycin‐based preferred regimens are 3 months of once‐weekly isoniazid plus rifapentine, 4 months of daily rifampin, or 3 months of daily isoniazid plus rifampin. Prescribing providers or pharmacists who are unfamiliar with rifampin and rifapentine might confuse the two drugs. They are not interchangeable, and caution should be taken to ensure that patients receive the correct medication for the intended regimen. Preference for these rifamycin‐based regimens was made on the basis of effectiveness, safety, and high treatment completion rates. The two alternative treatment regimens are daily isoniazid for 6 or 9 months; isoniazid monotherapy is efficacious but has higher toxicity risk and lower treatment completion rates than shorter rifamycin‐based regimens. In summary, short‐course (3‐ to 4‐month) rifamycin‐based treatment regimens are preferred over longer‐course (6‐9 month) isoniazid monotherapy for treatment of LTBI. These updated guidelines can be used by clinicians, public health officials, policymakers, health care organizations, and other state and local stakeholders who might need to adapt them to fit individual clinical circumstances.

surgery,transplantation
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

Haileyesus Getahun,Alberto Matteelli,Ibrahim Abubakar,Mohamed Abdel Aziz,Annabel Baddeley,Draurio Barreira,Saskia Den Boon,Susana Marta Borroto Gutierrez,Judith Bruchfeld,Erlina Burhan,Solange Cavalcante,Rolando Cedillos,Richard Chaisson,Cynthia Bin-Eng Chee,Lucy Chesire,Elizabeth Corbett,Masoud Dara,Justin Denholm,Gerard de Vries,Dennis Falzon,Nathan Ford,Margaret Gale-Rowe,Chris Gilpin,Enrico Girardi,Un-Yeong Go,Darshini Govindasamy,Alison D Grant,Malgorzata Grzemska,Ross Harris,C Robert Horsburgh Jr,Asker Ismayilov,Ernesto Jaramillo,Sandra Kik,Katharina Kranzer,Christian Lienhardt,Philip LoBue,Knut Lönnroth,Guy Marks,Dick Menzies,Giovanni Battista Migliori,Davide Mosca,Ya Diul Mukadi,Alwyn Mwinga,Lisa Nelson,Nobuyuki Nishikiori,Anouk Oordt-Speets,Molebogeng Xheedha Rangaka,Andreas Reis,Lisa Rotz,Andreas Sandgren,Monica Sañé Schepisi,Holger J Schünemann,Surender Kumar Sharma,Giovanni Sotgiu,Helen R Stagg,Timothy R Sterling,Tamara Tayeb,Mukund Uplekar,Marieke J van der Werf,Wim Vandevelde,Femke van Kessel,Anna van't Hoog,Jay K Varma,Natalia Vezhnina,Constantia Voniatis,Marije Vonk Noordegraaf-Schouten,Diana Weil,Karin Weyer,Robert John Wilkinson,Takashi Yoshiyama,Jean Pierre Zellweger,Mario Raviglione

DOI: https://doi.org/10.1183/13993003.01245-2015

Abstract:Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3-4 month isoniazid plus rifampicin; or 3-4 month rifampicin alone.
Effect of Different Interventions for Latent Tuberculosis Infections in China: a Model-Based Study

Zexuan Wen,Tao Li,Wenlong Zhu,Wei Chen,Hui Zhang,Weibing Wang

DOI: https://doi.org/10.1186/s12879-022-07465-5

IF: 3.7

2022-01-01

BMC Infectious Diseases

Abstract:Background Tuberculosis (TB) has a serious impact on people’s health. China is one of 30 countries that has a high TB burden. As the currently decreasing speed of the incidence of TB, the WHO’s goal of “End TB Strategy” is hard to achieve by 2035. As a result, a SEIR model that determines the impact of different tuberculosis preventive treatments (TPTs) in different age groups, and the effect of different interventions on latent TB infections (LTBIs) in China is developed. Methods A Susceptible-Exposed-Infectious-Recovered (SEIR) model was established. Goodness-of-fit tests were used to assess model performance. Predictive analysis was used to assess the effect of different interventions on LTBIs and achieving the goals of the “End TB Strategy”. Results The Chi-square test indicated the model provided a good statistical fit to previous data on the incidence of TB (χ 2 = 0.3085, p > 0.999). The 1HP treatment regimen (daily rifapentine + isoniazid for 4 weeks) was most effective in reducing the number of TB cases by 2035. The model indicated that several strategies could achieve the 2035 target of the “End TB Strategy”: completion of active case finding (ACF) for LTBI and TPT nation-wide within 5 years; completion of ACF for LTBIs and TPT within 2 years in high-incidence areas; completion of TPT in the elderly within 2 years; or introduction of a new vaccine in which the product of annual doses and vaccine efficiency in the three age groups above 14 years old reached 10.5 million. Conclusion The incidence of TB in China declined gradually from 2005 to 2019. Implementation of ACF for LTBIs and TPT nation-wide or in areas with high incidence, in the elderly, or administration of a new and effective vaccine could greatly reduce the number of TB cases and achieve the 2035 target of the “End TB Strategy” in China.
Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial

Henan Xin,Xuefang Cao,Haoran Zhang,Boxuan Feng,Ying Du,Bin Zhang,Dakuan Wang,Zisen Liu,Ling Guan,Fei Shen,Xueling Guan,Jiaoxia Yan,Yijun He,Yongpeng He,Zhusheng Quan,Shouguo Pan,Jianmin Liu,Qi Jin,Lei Gao

DOI: https://doi.org/10.1183/13993003.02359-2021

IF: 24.3

2021-11-11

European Respiratory Journal

Abstract:Background Enlarging tuberculosis (TB) preventive treatment among at-risk populations is a critical component of the End TB Strategy. It is urgently needed to develop suitable latent tuberculosis infection (LTBI) testing and treatment tools according to local TB epidemic and available resources in worldwide. Methods Based on an open-labeled randomised controlled trial conducted since 2015 among rural residents aged 50–70 years with LTBI, the protective efficacy of the 6-week twice-weekly regimen of rifapentine plus isoniazid was further evaluated in a 5-year follow-up survey. Results A total of 1298 treated participants and 1151 untreated controls were included in the 5-year protective efficacy analysis. In the per-protocol analysis, the incidence rate was 0.49/100 person-years (95% confidence interval (CI): 0.30–0.67) in the untreated control group and 0.19/100 person-years (95% CI: 0.07–0.32) in the treated group, the protection rate was 61.22%. Subgroup analysis showed that the protection rate was 76.82% in the per-protocol analysis among participants with baseline IFN-γ levels in the highest quartile (≥3.25 IU·mL −1 ). The multiple logistic regression analysis indicated that participants with baseline BMI <18.5 kg·m −2 and with pulmonary fibrotic lesions had increased hazard of developing active disease with an adjusted hazard ratio (aHR) of 3.64 (95% CI: 1.20–11.00) and 5.99 (95% CI: 2.20–16.27), respectively. In addition, individuals with higher baseline IFN-γ levels showed an increased risk of TB occurrence (aHR 2.27, 95% CI 1.13–4.58). Conclusions Our findings suggested the 6-week twice-weekly regimen of rifapentine plus isoniazid for LTBI treatment might be an optional tool for TB control in Chinese population.

respiratory system
Detection and preventive treatment of latent tuberculosis infection in immunocompromised patients

Qiao-ling RUAN,Xi-tian HUANG,Xue-feng LIU,Li-min CAI,Ling-yun SHAO,Wen-hong ZHANG

DOI: https://doi.org/10.3969/j.issn.1000-6621.2017.07.020

2017-01-01

Abstract:The latent tuberculosis infection (LTBI) detection and preventive treatment in the immunocompromised patients is one of the key challenges of tuberculosis (TB) control.Immunocompromised patients,including the patients with human immunodeficiency virus (HIV) infection,the patients with immune-mediated inflammatory diseases,the transplant candidates and recipients,are especially susceptible to TB.A targeted detection of LTBI in these high-risk groups is a precondition for providing the preventive treatment of TB.The performance of the two immunodiagnostic tests (interferon-gamma release assay and tuberculin skin test) is highly variable among different immunocompromised groups,so the selection of an appropriate screening strategy is very important.Preventive treatment of LTBI can reduce the risk of TB development,but the treatment regimens and the time of treatment can be different among different categories of compromised patients,and further researches are needed.
Incidence and Risk Factors of Active Tuberculosis Among Hospitalized Patients with Latent Tuberculosis Infection in China: A Cohort Study

Ye Liu,Lifan Zhang,Yan Chen,Guiren Ruan,Yuchen Liu,Shi Chen,Lantian Xie,Fengying Wu,Xiaochun Shi,Xiaoqing Liu

DOI: https://doi.org/10.2147/idr.s447245

2024-03-12

Infection and Drug Resistance

Abstract:Ye Liu, 1, &ast Lifan Zhang, 1– 4, &ast Yan Chen, 1, &ast Guiren Ruan, 1– 3 Yuchen Liu, 1 Shi Chen, 1 Lantian Xie, 1 Fengying Wu, 1 Xiaochun Shi, 1– 3 Xiaoqing Liu 1– 4 1 Division of Infectious Diseases, Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Beijing, People's Republic of China; 3 Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 4 Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaochun Shi; Xiaoqing Liu, Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan No. 1, Beijing, 100005, People's Republic of China, Email ; Background: The population with latent tuberculosis infection (LTBI) represents a potential pool of patients with active tuberculosis (ATB). T-SPOT.TB is an important test tool for screening LTBI. Owing to the large population of LTBI patients in China, it is necessary to identify a high-risk group for LTBI and enlarge tuberculosis preventive treatment (TPT) to reduce the incidence of ATB. Methods: Hospitalized patients with positive T-SPOT.TB results were recruited from January 2013 to December 2016. Patients with ATB were excluded. Basic information was collected and the development of ATBs was examined during follow-up. The life-table method was used to calculate cumulative incidence rates. Potential risk factors were analyzed through Cox regression analysis. Results: A total of 1680 patients with LTBI were recruited in the follow-up cohort, and 377 (22.44%) patients dropped out. With a median follow-up time of 81 months [interquartile range (IQR):61– 93], 19 of 1303 patients with LTBI developed ATB. The 1-year incidence of ATB was 614 per 100,000 individuals [95%confidence interval (95% CI):584– 644]. Over 5-year period, the cumulative incidence of ATB was 1496 per 100,000 [95% CI:1430– 1570], and the incidence density was 240 per 100,000 person-years[95% CI:144– 375]. In the Cox regression model, exposure of pulmonary tuberculosis (PTB) [adjusted hazard ratio (aHR)=10.557, 95% CI:2.273– 49.031], maximum daily dosage of glucocorticoids (GCs)≥ 50 mg/d (aHR=2.948, 95% CI:1.122– 7.748), leflunomide (LEF) treatment (aHR=8.572, 95% CI:2.222 − 33.070), anemia (aHR=2.565, 95% CI:1.015– 6.479) and T-SPOT.TB level≥ 300SFCs/10 6 PBMCs (aHR=4.195, 95% CI:1.365– 12.892) were independent risk factors for ATB development in LTBI patients. Conclusion: The incidence of ATB is significantly higher in hospitalized patients with LTBI than in the general population. The exposure history of PTB, maximum daily dosage of GCs≥ 50 mg/day, LEF treatment, anemia, and T-SPOT.TB level≥ 300SFCs/10 6 PBMCs, were the risk factors of tuberculosis reactivation. Hospitalized LTBI patients with the above factors may need TPT. Keywords: latent tuberculosis infection, active tuberculosis, incidence, risk factors Tuberculosis (TB) is an important infectious disease caused by Mycobacterium tuberculosis (MTB) that threatens human health. The Global TB Report 2022 noted that 10.6 million new TB cases were diagnosed in 2021, increasing of 3.6% over the previous year. China is one of the 30 high-burden countries. The WHO Health Organization estimated that China has 780,000 new TB patients, with an incidence of 55 per 100,000 in 2021. 1 The cumulative incidence of TB has reduced by only 11% from 2015 to 2021, far from the target of the Global End TB Strategy, which states that the incidence of TB should be reduced by 20% in 2020. 2,3 Latent tuberculosis infection (LTBI) is defined as a persistent immune response to stimulation by MTB antigens without active tuberculosis (ATB). LTBI has a 5% to 10% lifetime risk of progressing to ATB, mostly within 5 years of the initial infection. 4 There are two methods recommended by WHO for screening LTBI: tuberculin skin test (TST) and Interferon-γ release assays (IGRAs), including T-SPOT.TB. 5 The prevalence was estimated to be 20.3%, with nearly 300 million cases in China. 6 S -Abstract Truncated-

pharmacology & pharmacy,infectious diseases
Large gap between attitude and action in tuberculosis preventive treatment among tuberculosis-related healthcare workers in eastern China

Fei Wang,Yanli Ren,Kui Liu,Ying Peng,Xinyi Chen,Bin Chen,Jianmin Jiang

DOI: https://doi.org/10.3389/fcimb.2022.991400

IF: 6.073

2022-10-08

Frontiers in Cellular and Infection Microbiology

Abstract:Healthcare workers (HCWs) are at a high risk for latent tuberculosis infection (LTBI) because of occupational exposure, and the attitudes and behaviors of frontline tuberculosis (TB)-related HCWs toward preventive treatment of LTBI in eastern China remain unknown. This study aimed to explore the attitudes and actual behaviors of TB-related HCWs toward TB preventive treatment (TPT) and to analyze the relevant factors influencing the attitudes of HCWs. A stratified random sample of 28 TB-designated hospitals was selected in Zhejiang Province, China. All TB-related HCWs in the selected hospitals were recruited to answer questionnaires and were tested for LTBI by the TB interferon gamma release assay. TPT use was assessed two years after the survey. Univariate analysis and binary logistic regression models were used to analyze the factors influencing the TPT intention of HCWs. A total of 318 TB-related HCWs were recruited from 28 TB-designated hospitals; 62.3% of them showed positive attitudes toward TPT, while the rest were reluctant to treat positive LTBI prophylactically. binary logistic regression analysis revealed that the factors influencing the attitudes of HCWs were mainly education level, household income, history of alcohol consumption, and workplace. The IGRA test found that 35.2% (112/318) of HCWs tested positive for LTBI. Most people refused treatment because of drug side effects, followed by the belief that treatment was ineffective, wanting to wait until the onset of the disease, and that it was too much trouble to take the medication. According to the results of a follow-up survey, only one of these HCWs underwent TPT, and the consistency rate of attitudes and behaviors was 36.6% (41/112). This study reveals different attitudes toward TPT among TB-associated HCWs in eastern China and a large gap between attitudes and actual action. The management of HCWs with LTBI still needs further strengthening.

immunology,microbiology
Incidence of active tuberculosis in HIV-infected individuals not receiving universal tuberculosis preventive treatment

Ling Chen,Lifan Zhang,Leidan Zhang,Liyuan Zheng,Jia Tang,Xiaojing Song,Yanling Li,Xiaoxia Li,Wei Lv,Ling Luo,Fuping Guo,Xinchao Liu,Guiren Ruan,Huanling Wang,Yang Han,Taisheng Li,Wei Cao

DOI: https://doi.org/10.1097/cm9.0000000000003394

IF: 6.133

2024-12-04

Chinese Medical Journal

Abstract:To the Editor : Tuberculosis (TB) is the leading cause of death in people living with HIV (PLWH) globally. Given the increased risk of TB infection, TB preventive therapy (TPT) is recommended for PLWH to prevent TB activation and to reduce relevant mortality. However, the implementation of TPT remains weak with only 21% of eligible PLWH initiated on TPT globally in 2021, [ 1 ] primarily due to the implementation challenges in developing countries. The low completion rate of TPT may be attributed to various reasons, including socio-economic factors, individual behaviors (medication adherence, lack of knowledge, etc.), unstable supply chain of anti-TB drugs, and insufficient understanding of TB treatment guidelines. China has always been regarded as a region with high TB burden. Therefore, conditional TB prophylaxis has been recommended in national guidelines for HIV-infected patients since 2006, with emphasis on those with CD4 + T count <200 cells/μL, or those with positive tests of latent TB screening, preferred using interferon γ release assay (IGRA). Since 2021, universal TB prophylaxis strategy has been recommended following the World Health Organization (WHO) guidelines. However, in real practice, HIV-infected individuals seldomly receive universal TPT when initiating antiretroviral therapy (ART) in most centers. Nevertheless, there is little report on the incidence of active TB development following ART initiation of HIV-infected individuals in China. In addition, whether a universal prophylaxis strategy would benefit the population also depends on the population-based prevalence of TB activation, as well as therapeutic cost and drug-related adverse events. Therefore, we here aim to compile the prevalence of active TB of PLWH in the first five years of initiating ART in one comprehensive referring center in Beijing China, providing real-world data for a more individualized TPT in HIV-infected individuals.

medicine, general & internal
Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

Liping Yan,Xiaohong Kan,Limei Zhu,Kaijin Xu,Jianjun Yin,Li Jie,Yong Li,Ji Yue,Wenyu Cui,Juan Du,Lihua Wang,Shouyong Tan,Xiangao Jiang,Zhong Zeng,Shenghui Xu,Lin Wang,Yu Chen,Weiguo He,Xusheng Gao,Dapeng Bai,Chengjie Zhao,Xiaofeng Yan,Yuyin Zhu,Yumei Fan,Lanpin Xie,Aihua Deng,Qing Zhang,Heping Xiao

DOI: https://doi.org/10.1016/j.clinthera.2018.01.013

IF: 3.637

2018-01-01

Clinical Therapeutics

Abstract:Purpose: We designed a prospective, multicenter, randomized, controlled study to assess a 5-month regimen compared with the standard regimen on previously treated patients with pulmonary tuberculosis (TB). Methods: We enrolled 917 sputum smear-positive patients undergoing additional treatment in 27 major tuberculosis hospitals in China. Patients were randomly assigned to a test group (n -= 626)treated with a 5-month regimen of moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide or a reference group (n = 291) treated with an 8-month regimen of isoniazid, rifampicin, and streptomycin. All patients with a favorable response were followed up for 5 years after the end of treatment. Findings: Of the study patients, 61 in the test group and 19 in the reference group had multidrug-resistant (MDR) TB. The treatment success rate in the study group was 74.12%, which was significantly higher than the 67.70% in the reference group (P = 0.04), whereas the treatment success rate of patients with MDR-TB was not significantly different between the test and reference groups (70.5% vs 63.1%, P =0.79). The adverse effects rates in the test and reference groups were 7.4% and 3.1%, respectively (P = .01). The difference in the TB recurrence rates between the group arm (9.6%) and the reference group (21.8%) was statistically significant (P < 0.001). (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
P482 Selective Prophylactic Anti-Tuberculosis Strategy is Superior for Chinese Patients with Inflammatory Bowel Disease Receiving Infliximab Treatment: a Multi-Centre Retrospective Study

L. Ye,M. Chen,X. Gao,K. Wu,Z. Ran,H. Yang,Z. Liu,Q. Cao

DOI: https://doi.org/10.1093/ecco-jcc/jjy222.606

2019-01-01

Abstract:During anti-TNF therapy, inflammatory bowel disease (IBD) patients either with or without latent tuberculosis infection (LTBI) active TB can develop. It remains unclear whether IBD patients without LTBI receiving prophylactic anti-TB has any clinical value or which prophylactic anti-TB strategy (for both LTBI and non-LTBI or only for LTBI) is superior. Furthermore, the optimum treatment regimen for IBD patients with LTBI receiving infliximab (IFX) in China are both unclear. This study was to investigate the optimal prophylactic anti-TB strategies and treatment regimens in Chinese IBD subjects receiving IFX treatment. IBD patients receiving IFX at 18 academic hospitals in China were enrolled. Incidence and risk factors for active TB during IFX treatment were studied. The incidence of active TB in IBD patients with IFX therapy receiving selective (strategy I: only anti-TB prophylaxis for LTBI) and conventional (strategy II: anti-TB prophylaxis for both LTBI and non-LTBI) prophylactic anti-TB strategies was compared. Further subgroup analysis investigated the incidence rate of active TB in LTBI and non-LTBI patients and examined effective prophylactic treatment regimens for LTBI. A total of 1968 IBD patients receiving IFX treatment were enrolled. The incidence rate of TB was 999.07 per 100000 population per year. At baseline, 166 cases (8.43%) tested positive for LTBI and 1802 cases negative for LTBI prior to IFX treatment. Of 1433 cases receiving strategy I and 483 cases receiving strategy II, 10 and 5 cases developed active TB, respectively. Figure 1. The incidence of active TB in IBD patients with IFX therapy receiving different strategy. And the incidence of active TB was not significantly reduced in IBD patients receiving strategy I compared with those receiving strategy II (0.07% vs. 1.04%, p = .67). The incidence of active TB (2.63% vs. 11.54%, p = .048) was significantly reduced but not eradicated in LTBI patients receiving prophylactic anti-TB therapy during IFX treatment, but these findings were not seen in non-LTBI patients. Figure 2. The incidence of active TB in LTBI and non-LTBI patients. Furthermore, INH treatment for 6 months significantly decreased the incidence rate of active TB (0% vs. 11.54%, p = 0.045) in LTBI patients. Selective prophylactic anti-TB strategy may be superior for Chinese patients with IBD receiving IFX treatment and INH treatment for 6 months could be an effective treatment regimen for LTBI.
Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

Lingna Ye,Thomas P. Chapman,Zhenzhen Wen,Lang Lin,Yun Qiu,Zhanju Liu,Zhihua Ran,Jiaming Qian,Kaichun Wu,Xiang Gao,Pinjin Hu,Minhu Chen,Simon P. L. Travis,Qian Cao

DOI: https://doi.org/10.1111/apt.16130

IF: 9.524

2021-01-01

Alimentary Pharmacology & Therapeutics

Abstract:Background Anti-tumour necrosis factor (anti-TNF) therapy increases the risk of tuberculosis (TB). Given limitations of screening techniques, it remains uncertain if patients receiving anti-TNF in TB endemic regions should be screened for latent infection with chemoprophylaxis restricted to those with proven infection, or if all patients should receive chemoprophylaxis. Aims To compare the incidence of active TB with infliximab (IFX) following targeted and universal TB chemoprophylaxis, and to determine the rates of adverse events (AE) related to TB chemoprophylaxis Methods A multi-centre retrospective cohort study was performed at 18 hospitals in China of 1968 adult patients with IBD receiving IFX from 2009 to 2017. TB screening prior to IFX was performed with chest X-ray and/or computed tomography [CT] and immune reactivity testing (interferon-gamma release assay and/or tuberculin skin test). Patients were followed-up for a minimum of 3 months after IFX discontinuation, or until last hospital visit if IFX therapy was ongoing. Targeted strategy was defined as TB chemoprophylaxis only for patients with a positive latent TB screen, with universal strategy defined as TB chemoprophylaxis for all patients. Results Mean follow-up was 1.07 +/- 0.87 years with a total follow-up of 2102 patient-years. There were 1433 patients in the targeted and 483 patients in the universal TB chemoprophylaxis groups, with no significant difference in the incidence rates of active TB between groups (673.3 per 100 000 population per year vs 891.5 per 100 000 population per year, P = 0.60). In the targeted group, 55/1433 patients received TB chemoprophylaxis compared with 483/483 in the universal group, with significantly fewer AEs related to TB chemoprophylaxis in the targeted compared to the universal group (0.35% (5/1433) vs 6.8% (33/483), P < 0.05). Conclusions In this study of patients receiving IFX in a TB endemic area, universal chemoprophylaxis was not associated with a reduced risk of active TB when compared to a targeted chemoprophylaxis strategy, and AEs were more common. This supports the use of targeted TB chemoprophylaxis when anti-TNF therapy is initiated in TB endemic regions.
Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion

Yejin Kim,Kil Seong Bae,Ui Yoon Choi,Seung Beom Han,Jong-Hyun Kim

DOI: https://doi.org/10.3346/jkms.2024.39.e64

2024-01-01

Journal of Korean Medical Science

Abstract:BACKGROUND: The treatment of pediatric patients with latent tuberculosis infection (LTBI) is a crucial TB control strategy. LTBI is not a reportable communicable disease, and data regarding LTBI treatment in pediatric patients in Korea are scarce. This study aimed to investigate the prescription patterns and treatment completion rates among pediatric patients with LTBI in Korea by analyzing National Health reimbursement claims data.METHODS: We retrospectively analyzed outpatient prescription records for pediatric patients aged 18 or younger with LTBI-related diagnostic codes from 2016 to 2020. We compared the frequency of prescriptions for the standard treatment regimen (9 months of isoniazid [9H]) and an alternative treatment regimen (3 months of isoniazid plus rifampicin [3HR]). We also assessed the treatment incompletion rates by age group, treatment regimen, treatment duration, the level of medical facility, physician's specialty, and hospital location. We performed multivariable analysis to identify factors influencing treatment incompletion.RESULTS: Among the 11,362 patients who received LTBI treatment, 6,463 (56.9%) were prescribed the 9H regimen, while 4,899 (43.1%) received the 3HR regimen. Patients in the 3HR group were generally older than those in the 9H group. The proportion of 3HR regimen prescriptions significantly greater in the later period (2018-2020), in primary hospitals, under the management of non-pediatric specialists, and in metropolitan regions. The overall treatment incompletion rate was 39.7% (9H group: 46.9%, 3HR group: 30.3%). In the multivariable analysis, 9H regimen prescription was the strongest factor associated with treatment incompletion (adjusted odds ratio, 2.42; 95% confidence interval, 2.20-2.66; <i>P</i> < 0.001). Additionally, management in a primary hospital, a hospital's location in a non-metropolitan region, and management by a non-pediatric specialist were also significant risk factors for treatment incompletion.CONCLUSION: Our study results suggest that promoting the use of 3HR regimen prescriptions could be an effective strategy to enhance treatment completion. Physicians in primary hospitals, hospitals located in non-metropolitan regions, and physicians without a pediatric specialty require increased attention when administering LTBI treatment to pediatric patients to ensure treatment completion.

medicine, general & internal
Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study.

Lei Gao,Haoran Zhang,Henan Xin,Jianmin Liu,Shouguo Pan,Xiangwei Li,Ling Guan,Fei Shen,Zisen Liu,Dakuan Wang,Xueling Guan,Jiaoxia Yan,Hengjing Li,Boxuan Feng,Xuefang Cao,Yu Chen,Wei Cui,Zongde Zhang,Yu Ma,Xiaoyou Chen,Xinhua Zhou,Qi Jin

DOI: https://doi.org/10.1183/13993003.01470-2018

IF: 24.3

2018-01-01

European Respiratory Journal

Abstract:Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy. In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50-69 years with LTBI in China. Due to the increasingly rapid growth and unexpected high frequency of adverse effects, the treatments were terminated early (after 8 weeks for the once-weekly regimen and after 6 weeks for the twice-weekly regimen). In the modified intention-to-treat analysis on the completed doses, the cumulative rate of active disease during 2 years of follow-up was 1.21% (14 out of 1155) in the untreated controls, 0.78% (10 out of 1284) in the group that received the 8-week once-weekly regimen and 0.46% (six out of 1299) in the group that received the 6-week twice-weekly regimen. The risk of active disease was decreased, with an adjusted hazard ratio of 0.63 (95% CI 0.27-1.43) and 0.41 (95% CI 0.15-1.09) for the treatments, respectively. No significant difference was found in the occurrence of hepatotoxicity (1.02% (13 out of 1279) versus 1.17% (15 out of 1279); p=0.704). The short regimens tested must be used with caution among the elderly because of the high rates of adverse effects. Further work is necessary to test the ultrashort regimens in younger people with LTBI.
2: A PILOT STUDY OF EVALUATION OF GUIDELINES ADHERENCE FOR LATENT TUBERCULOSIS INFECTION PATIENTS USING TNF-ANTAGONISTS IN A MEDICAL CENTER IN TAIWAN

Chih-Sheng Lin,Man-Lih Yao,Chih-Fang Chen,Wei-Ying Lee

DOI: https://doi.org/10.1136/bmjopen-2016-015415.2

IF: 3.006

2017-02-01

BMJ Open

Abstract:Background and aims: Use of anti-TNF agents increases the risk of TB, especially in Asian countries. The guideline suggested that the treatment of latent TB infection (LTBI) is recommended with oral isoniazid (INH) nine months and used TNF-α antagonist four weeks after treatment. However, the TB infection prevention by using TNF-α antagonist remains unclear in Taiwan. We evaluated the adherence rates of patients received anti -TNF agents with latent tuberculosis infection (LTBI) prophylaxis treatment. Methods: Retrospectively collected the medical records of outpatient received adalimumab from Jan. 2014 to Dec. 2015. Brio Query version 6 as a computer program to collect patient information Results: There are 49 patients included in this study. Eighteen percent (9/49) of the patients received LTBI prophylaxis. Seventy eight percent (7/9) patients were found of positive QuantiFERON test, and 22% (2/9) revealed intermediate results. One of the patient with Anti-HBc (+) and HCV (+) ceased treatment four months later. He was found of ALT level increase to 98 IU/L while taking INH again in the first month. The liver function returned to normal after INH discontinuation. The other 89% (8/9) completed 9 months treatment course. One of them is hepatitis B carrier with liver function impairment after taking medicine for six months. This individual case was done in closely monitored by doctor, and hepatic function return to normal three months after treatment. Conclusion: This study shows the risk of INH-induced liver function impairment is higher than the other country. The QuantiFERON testing are highly recommend if patients taking TNF-α inhibitor and another therapy instead seems to be more in line with prophylaxis for tuberculosis in Taiwan.

medicine, general & internal
Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis

Mercedes Yanes-Lane,Edgar Ortiz-Brizuela,Jonathon R Campbell,Andrea Benedetti,Gavin Churchyard,Olivia Oxlade,Dick Menzies

DOI: https://doi.org/10.1371/journal.pmed.1003738

2021-09-14

Abstract:Background: Tuberculosis (TB) preventive therapy (TPT) is an essential component of care for people living with HIV (PLHIV). We compared efficacy, safety, completion, and drug-resistant TB risk for currently recommended TPT regimens through a systematic review and network meta-analysis (NMA) of randomized trials. Methods and findings: We searched MEDLINE, Embase, and the Cochrane Library from inception through June 9, 2020 for randomized controlled trials (RCTs) comparing 2 or more TPT regimens (or placebo/no treatment) in PLHIV. Two independent reviewers evaluated eligibility, extracted data, and assessed the risk of bias. We grouped TPT strategies as follows: placebo/no treatment, 6 to 12 months of isoniazid, 24 to 72 months of isoniazid, and rifamycin-containing regimens. A frequentist NMA (using graph theory) was carried out for the outcomes of development of TB disease, all-cause mortality, and grade 3 or worse hepatotoxicity. For other outcomes, graphical descriptions or traditional pairwise meta-analyses were carried out as appropriate. The potential role of confounding variables for TB disease and all-cause mortality was assessed through stratified analyses. A total of 6,466 unique studies were screened, and 157 full texts were assessed for eligibility. Of these, 20 studies (reporting 16 randomized trials) were included. The median sample size was 616 (interquartile range [IQR], 317 to 1,892). Eight were conducted in Africa, 3 in Europe, 3 in the Americas, and 2 included sites in multiple continents. According to the NMA, 6 to 12 months of isoniazid were no more efficacious in preventing microbiologically confirmed TB than rifamycin-containing regimens (incidence rate ratio [IRR] 1.0, 95% CI 0.8 to 1.4, p = 0.8); however, 6 to 12 months of isoniazid were associated with a higher incidence of all-cause mortality (IRR 1.6, 95% CI 1.2 to 2.0, p = 0.02) and a higher risk of grade 3 or higher hepatotoxicity (risk difference [RD] 8.9, 95% CI 2.8 to 14.9, p = 0.004). Finally, shorter regimens were associated with higher completion rates relative to longer regimens, and we did not find statistically significant differences in the risk of drug-resistant TB between regimens. Study limitations include potential confounding due to differences in posttreatment follow-up time and TB incidence in the study setting on the estimates of incidence of TB or all-cause mortality, as well as an underrepresentation of pregnant women and children. Conclusions: Rifamycin-containing regimens appear safer and at least as effective as isoniazid regimens in preventing TB and death and should be considered part of routine care in PLHIV. Knowledge gaps remain as to which specific rifamycin-containing regimen provides the optimal balance of efficacy, completion, and safety.
Diagnosis and treatment of latent infection with Mycobacterium tuberculosis.

Cynthia Bin-Eng Chee,Martina Sester,Wenhong Zhang,Christoph Lange

DOI: https://doi.org/10.1111/resp.12002

IF: 6.9

2013-01-01

Respirology

Abstract:In clinical practice, latent infection with Mycobacterium tuberculosis is defined by the presence of an M. tuberculosis-specific immune response in the absence of active tuberculosis. Targeted testing of individuals from risk groups with the tuberculin skin test or an interferon-gamma release assay is currently the best method to identify those with the highest risk for progression to tuberculosis. Positive predictive values of the immunodiagnostic tests are substantially influenced by the type of test, the age of the person who is tested, the prevalence of tuberculosis in the society and the risk group to which the person belongs. As a general rule, testing should only be offered when preventive chemotherapy will be accepted in the case of a positive test result. Preventive chemotherapy can effectively protect individuals at risk from the development of tuberculosis, although at least 3 months of combination therapy or up to 9 months of monotherapy are required, and overall acceptance rate is low. Improvements of the current generation of immunodiagnostic tests could substantially lower the number of individuals that need to be treated to prevent a case of tuberculosis. If shorter treatment regimens were equally effective than those currently recommended, acceptance of preventive chemotherapy could be much improved.
Tuberculosis infection screening in children with close contact: a hospital-based study

Lin Sun,Xue Qi,Yajie Guo,Hui Qi,Jieqiong Li,Xirong Wu,Qingqin Yin,Yan Guo,Baoping Xu,Yacui Wang,Qi Jin,Lei Gao,Adong Shen

DOI: https://doi.org/10.1186/s12879-021-06480-2

IF: 3.7

2021-08-13

BMC Infectious Diseases

Abstract:Abstract Background Identifying and prioritizing at-risk populations is critical for pediatric tuberculosis control. We aimed to identify a latent tuberculosis infection (LTBI) screening strategy that is appropriate for the Chinese context among children with different TB exposure levels and to explore its clinical importance. Methods During 2013–2015, we enrolled hospitalized children with suspected respiratory infectious disease (RID) for LTBI screening using the tuberculin skin test (TST) and interferon-γ release assay (IGRA) T-SPOT.TB as part of a work up for their RID. Participants with confirmed diagnosis were classified into three subgroups according to level of exposure to TB: no reported contact risk, with household contact risk, and with non-household contact risk. Results A total 6202 children (median age: 4.76 years; interquartile range: 1.0–8.0 years) were enrolled. Children with no reported contact risk had the lowest proportions of positive results for the IGRA (0.7%) and TST (3.3%). The proportion of positive results for each test was higher for household contacts than non-household contacts. The TST positive proportion was much higher than that for the IGRA in all three groups. Children with IGRA+/TST+ results had larger indurations than those with IGRA− /TST+ results (15 mm vs. 13 mm, P = 0.02). For IGRA, older age (> 5 years) and non-household or household contact risk were associated with a positive result. Conclusions Positive IGRA results in children with a contact risk can serve as a critical reference for LTBI management. IGRA can be used, in preference to TST, for Chinese children with a TB exposure risk.

infectious diseases

Outcomes of wavefront-optimized surface ablation.

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Optimal conditions for long-term photoreceptor cell rescue in RCS rats: the necessity for healthy RPE transplants.

Updates on the Risk Factors for Latent Tuberculosis Reactivation and Their Managements.

Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

Effect of Different Interventions for Latent Tuberculosis Infections in China: a Model-Based Study

Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial

Detection and preventive treatment of latent tuberculosis infection in immunocompromised patients

Incidence and Risk Factors of Active Tuberculosis Among Hospitalized Patients with Latent Tuberculosis Infection in China: A Cohort Study

Large gap between attitude and action in tuberculosis preventive treatment among tuberculosis-related healthcare workers in eastern China

Incidence of active tuberculosis in HIV-infected individuals not receiving universal tuberculosis preventive treatment

Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

P482 Selective Prophylactic Anti-Tuberculosis Strategy is Superior for Chinese Patients with Inflammatory Bowel Disease Receiving Infliximab Treatment: a Multi-Centre Retrospective Study

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion

Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study.

2: A PILOT STUDY OF EVALUATION OF GUIDELINES ADHERENCE FOR LATENT TUBERCULOSIS INFECTION PATIENTS USING TNF-ANTAGONISTS IN A MEDICAL CENTER IN TAIWAN

Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis

Diagnosis and treatment of latent infection with Mycobacterium tuberculosis.

Tuberculosis infection screening in children with close contact: a hospital-based study